Loading
A phase 2 trial of Izalontamab brengitecan in small-cell lung cancer, run by Sichuan Baili Pharmaceutical Co., Ltd., now recruiting.
A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Extensive-stage Small Cell Lung Cancer is a phase 2 interventional study registered as NCT06437509 by Sichuan Baili Pharmaceutical Co., Ltd., with 66 participants planned, started 2024-06-13 and due to reach its primary completion in 2026-12. Interventions recorded: BL-B01D1, PD-1 monoclonal antibody. Conditions listed: Extensive-stage Small-cell Lung Cancer. No results are recorded here; the registry entry is the source.
Shares Bispecific ADC, Izalontamab brengitecan, SystImmune / Sichuan Biokin, Extensive-stage small-cell lung cancer.
Shares Bispecific ADC, Izalontamab brengitecan, SystImmune / Sichuan Biokin, Antibody-drug conjugate (ADC).
Shares Bispecific ADC, Izalontamab brengitecan, SystImmune / Sichuan Biokin, Antibody-drug conjugate (ADC).
Shares Bispecific ADC, Izalontamab brengitecan, SystImmune / Sichuan Biokin, Antibody-drug conjugate (ADC).
Shares Bispecific ADC, Izalontamab brengitecan, SystImmune / Sichuan Biokin, Antibody-drug conjugate (ADC).
Shares Bispecific ADC, Izalontamab brengitecan, SystImmune / Sichuan Biokin, Antibody-drug conjugate (ADC).
Shares Bispecific ADC, Izalontamab brengitecan, SystImmune / Sichuan Biokin, Antibody-drug conjugate (ADC).
Shares Bispecific ADC, Izalontamab brengitecan, SystImmune / Sichuan Biokin, Antibody-drug conjugate (ADC).